Experimental donor CAR-T therapy tested in lymphoma – trial halted early
NCT ID NCT06256484
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a new therapy called ATA3219, which uses immune cells from a healthy donor to attack cancer cells in people with relapsed or refractory B-cell non-Hodgkin lymphoma. The study aimed to check safety and see if the treatment works, but it was stopped early after enrolling only one participant. Because the trial was so small, we cannot draw any conclusions about how well this therapy might work.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ATA3219 (a type of immune cell therapy called CAR-T, made from donor cells)
- What this could lead to
- If it works, this could offer a new treatment option for people with hard-to-treat B-cell lymphoma who have run out of standard therapies.
- What could go wrong
- This was a very early, small Phase 1 trial that was terminated after enrolling only 1 person, so we have very little data. The therapy may cause serious side effects like cytokine release syndrome or nervous system problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AdventHealth Cancer Institute
Orlando, Florida, 32804, United States
-
Fiona Stanley Hospital
Murdoch, Western Australia, 6150, Australia
-
Norton Cancer Institute - Saint Matthews
Louisville, Kentucky, 40207, United States
-
Princess Alexandra Hospital
Woolloongabba, Queensland, 4102, Australia
-
Sidney Kimmel Cancer Center - Jefferson Health
Philadelphia, Pennsylvania, 19107, United States
-
University of Virgina
Charlottesville, Virginia, 22908, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can a single shot build a cancer army inside the body?
- New combo therapy aims to boost remission in Hard-to-Treat lymphoma
- Engineered immune cells get a boost: new combo therapy targets Hard-to-Treat blood cancers
- Immune cells engineered to fight lymphoma enter human testing
- New combo aims to boost lymphoma control in older patients